gdc
PSSGuide_2020
Cervical Cancer

Drugs for Cervical Cancer

Here are the drugs and financial support services available to patients receiving treatment for Cervical Cancer.

Avastin (bevacizumab)

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Genentech offers 2 financial assistance programs for patients using Avastin:

Genentech BioOncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 120 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Hycamtin (topotecan hydrochloride injection)

Drug company: Novartis
800-245-5356

Hycamtin for injection is a topoisomerase inhibitor used, in combination with cisplatin, for the treatment of patients with stage IVB, recurrent or persistent carcinoma of the cervix

Novartis’ Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Hycamtin for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Hycamtin for free for 1 year, or until prescription drug coverage becomes available to them.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $62,450 or less for individuals, $84,550 or less for a couple, or $128,750 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Mvasi, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with chemotherapy (with paclitaxel and cisplatin, or with paclitaxel and topotecan), for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Amgen offers 2 financial assistance programs for patients using Mvasi:

Amgen FIRST STEP Program

With this program, eligible patients who have private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients who have limited or no insurance coverage and patients with Medicare Part D program who satisfy the income eligibility requirements, may receive Mvasi for free

Table. Drugs Prescribed for Cervical Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Hycamtin (topotecan hydrochloride injection)
  • Drug company
  • Novartis
  • Indication
  • Treatment of stage IVB, recurrent or persistent carcinoma of the cervix, in combination with cisplatin
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254
    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932
    Drug name (generic name)
  • Mvasi (bevacizumab-awwb)
  • Drug company
  • Amgen
  • Indication
  • Treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436

Last modified: April 13, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country